Approximately 20-40% of diffuse large B-cell lymphoma (DLBCL) patients experience relapsed or refractory disease after initial treatment with R-CHOP (a combination therapy regimen for DLBCL that combines chemotherapy drugs with rituximab). Polatuzumab vedotin is an antibody-drug conjugate (ADC) used to treat DLBCL, both in first-line treatment and for relapsed or refractory cases. At the 2025 …Read More >

Antibody‒drug conjugates (ADCs), which combine the advantages of monoclonal antibodies with precise targeting and payloads, show great potential as cancer therapies.  However, primary and secondary resistance is frequently observed.  The successful development of next generation ADCs necessitates the establishment of tumor models that address the mechanism of action underlying this resistance. At the 2025 World …Read More >

DNA-encoded library (DEL) technology has been recognized as a major screening method with unique advantages for offering vast chemical diversity and multiplexed affinity-based screening. Recently, solid-phase On-bead DEL, also known as one bead one compound (OBOC), has been developed to further expand DEL screening from affinity-based screening into biochemical activity screening. At the 2025 SLAS …Read More >

Chemical inducers of proximity (CIPs) are small molecules that induce the proximity of two biological targets, usually proteins. Molecular glues and PROteolysis TArgeting Chimeras (PROTACs®) are among the best-known CIPs. These molecules utilize the endogenous E3-based proteolysis pathway to induce proximity between the target protein and E3 ligase, thereby triggering targeted protein degradation. At the …Read More >

With advancements in drug design, there is resurging interest in drugs that form covalent bonds with their targets. Covalent drugs have the potential to provide enhanced potency and prolonged duration of action compared to non-covalent drugs. Emerging areas of interest include the development of reversible covalent inhibitors, covalent degraders, and covalent targeting of non-cysteine amino …Read More >

At the 2024 Protein & Antibody Engineering Summit (PEGS) Europe, Crelux presented a poster highlighting its drug discovery platform for the production and characterization of protein biologics and their antigens. This platform combines construct and expression scouting, customizable high-throughput protein purification, and affinity/kinetics determination using various biophysical techniques, as well as paratope and epitope mapping …Read More >

Psoriasis is a chronic autoimmune skin disease characterized by abnormal keratinocyte proliferation and infiltration of inflammatory cells.  The absence of a suitable animal model that accurately mimics the complex phenotype of psoriasis in humans has hindered the development of promising therapeutics to treat this condition. At SITC 2024, WuXi AppTec presented a poster showcasing the …Read More >

Vitiligo is an autoimmune disorder characterized by the progressive destruction of melanocytes in the skin. This condition is driven by the infiltration of endogenous autoreactive CD8+ T cells, which target and destroy melanocytes, resulting in the clinical manifestation of skin depigmentation. As a common acquired skin disease with no highly effective treatments, there is an …Read More >

Currently, there is a lack of efficient experimental strategies to collect high-quality proteome level data for protein-ligand interactions (PLIs).  At the 2024 ML Drug Discovery Symposium, WuXi AppTec presented a poster showcasing our advanced DELvision database, representing the first use of DNA-encoded library (DEL) technology for establishing a protein-DEL interaction database. The authors demonstrate how …Read More >